About Fujirebio
Fujirebio is a company based in Tokyo (Japan) founded in 1950. It operates as a Professional Services and Direct-to-Consumer (D2C). The company has 21 employees as of April 08, 2024. Fujirebio offers products and services including Lumipulse® G, INNO-LIA® Score Assays, and CanAg® Testing Solutions. Fujirebio operates in a competitive market with competitors including Roche, EKF, SonoSite, Cordant Health Solutions and NVision Imaging Technologies, among others.
- Headquarter Tokyo, Japan
- Employees 21 as on 08 Apr, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fujirebio Holdings, Inc.
- Date of Incorporation 16 Mar, 2017
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$430.84 K (USD)-2.55as on Mar 31, 2020
-
Net Profit
-$2.52 M (USD)-126.11as on Mar 31, 2020
-
EBITDA
-$2.55 M (USD)-106.69as on Mar 31, 2020
-
Latest Funding Round
Not available
- Investors
-
Employee Count
21
as on Apr 08, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fujirebio
Fujirebio offers a comprehensive portfolio of products and services, including Lumipulse® G, INNO-LIA® Score Assays, and CanAg® Testing Solutions.
Automated testing instrument for in-vitro diagnostics solutions.
Fully automated kits for diagnostic testing purposes.
Manual testing kits for various clinical diagnostics.
People of Fujirebio
Unlock access to complete
Product Management Team
14 people
Leadership Team
9 people
Software Development Team
6 people
Manufacturing Team
4 people
QA Team
2 people
Sales and Marketing
2 people
Human Resources and Administration
1 people
Sr. Team
1 people
Unlock access to complete
Funding Insights of Fujirebio
Investors in Fujirebio
Fujirebio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Alzheimer's Drug Discovery.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for Alzheimer's prevention, treatment, and cure are discovered.
|
Locked | Locked | Locked |
Investor details for Fujirebio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fujirebio
Investment portfolio details for Fujirebio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fujirebio
Detailed financials for Fujirebio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fujirebio Comparisons
Peer comparison for Fujirebio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fujirebio
Fujirebio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Roche, EKF, SonoSite, Cordant Health Solutions and NVision Imaging Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Point-of-care and laboratory blood analyzers are developed by EKF.
|
|
| Locked | Locked | Locked |
Hand-carried ultrasound systems for medical specialties are developed and distributed.
|
|
| Locked | Locked | Locked |
Drug testing services are offered for clinical trials and workplaces.
|
|
| Locked | Locked | Locked |
Medical imaging is provided through quantum technologies.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for immunoassay tests are provided to clinicians.
|
Detailed competitors of Fujirebio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fujirebio
Complete news archive for Fujirebio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fujirebio
Fujirebio was founded in 1950 and raised its 1st funding round 71 years after it was founded.
Fujirebio is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
As of Apr 08, 2024, the latest employee count at Fujirebio is 21.
Annual revenue of Fujirebio is $430.84K as on Mar 31, 2020.
Fujirebio is engaged in the development, manufacturing, and marketing of high-quality in-vitro diagnostics testing solutions globally. The company operates within the healthcare sector, focusing on innovative technologies and unique biomarkers with significant clinical value. Solutions are provided for various clinical areas including autoimmune diseases, neurodegeneration, and infectious diseases. Strategic acquisitions and collaborations with leading laboratories and institutions have enhanced capabilities, positioning Fujirebio as a key player in diagnostics.
Fujirebio offers Lumipulse® G, INNO-LIA® Score Assays, and CanAg® Testing Solutions.
Fujirebio has 1 investor. Key investors include Alzheimer's Drug Discovery.